92 related articles for article (PubMed ID: 2880460)
1. An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients.
Vågen R; Götestam KG
Acta Psychiatr Scand; 1986 Nov; 74(5):519-23. PubMed ID: 2880460
[TBL] [Abstract][Full Text] [Related]
2. Effects of mianserin in neuroleptic-induced parkinsonism.
Korsgaard S; Friis T
Psychopharmacology (Berl); 1986; 88(1):109-11. PubMed ID: 2868480
[TBL] [Abstract][Full Text] [Related]
3. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
Bersani G; Grispini A; Marini S; Pasini A; Valducci M; Ciani N
Clin Neuropharmacol; 1990 Dec; 13(6):500-6. PubMed ID: 2125857
[TBL] [Abstract][Full Text] [Related]
4. [A double-blind study on the effect of dexetimide in the control of neuroleptic-induced extrapyramidal side-effects].
Chen Y
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Aug; 24(4):197-9, 251. PubMed ID: 1683277
[TBL] [Abstract][Full Text] [Related]
5. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study.
Gjerden P; Bramness JG; Slørdal L
Br J Clin Pharmacol; 2009 Feb; 67(2):228-33. PubMed ID: 19094158
[TBL] [Abstract][Full Text] [Related]
6. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms.
Chouinard G; Annable L; Mercier P; Turnier L
Psychopharmacol Bull; 1987; 23(1):221-6. PubMed ID: 2885889
[No Abstract] [Full Text] [Related]
8. Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics.
Manos N; Lavrentiadis G; Gkiouzepas J
J Clin Psychiatry; 1986 Mar; 47(3):114-6. PubMed ID: 2869027
[TBL] [Abstract][Full Text] [Related]
9. [Considerations on projected pharmacology of antiparkinson agents].
Duchene-Marullaz P; Jalfre M; Hache J
Therapie; 1969; 24(4):683-8. PubMed ID: 5822006
[No Abstract] [Full Text] [Related]
10. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine.
Gjerden P; Slørdal L; Bramness JG
Br J Clin Pharmacol; 2009 Aug; 68(2):238-42. PubMed ID: 19694744
[TBL] [Abstract][Full Text] [Related]
11. Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal.
Rifkin A; Quitkin F; Kane J; Struve F; Klein DF
Arch Gen Psychiatry; 1978 Apr; 35(4):483-9. PubMed ID: 215095
[TBL] [Abstract][Full Text] [Related]
12. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
[TBL] [Abstract][Full Text] [Related]
13. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats.
Myhrer T; Enger S; Aas P
Pharmacol Biochem Behav; 2008 Jun; 89(4):633-8. PubMed ID: 18384867
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of trihexyphenidyl.
McInnis M; Petursson H
Acta Psychiatr Scand; 1985 Mar; 71(3):297-303. PubMed ID: 3984771
[TBL] [Abstract][Full Text] [Related]
15. Interaction of atropine-like drugs with dopamine-containing neurones in rat brain.
Bowers MB; Roth RH
Br J Pharmacol; 1972 Feb; 44(2):301-6. PubMed ID: 4148918
[TBL] [Abstract][Full Text] [Related]
16. Interactions between procyclidine and neuroleptic drugs. Some pharmacological and clinical aspects.
Bamrah JS; Kumar V; Krska J; Soni SD
Br J Psychiatry; 1986 Dec; 149():726-33. PubMed ID: 2878700
[TBL] [Abstract][Full Text] [Related]
17. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo.
Friis T; Christensen TR; Gerlach J
Acta Psychiatr Scand; 1983 Mar; 67(3):178-87. PubMed ID: 6134430
[No Abstract] [Full Text] [Related]
18. Abnormal involuntary movements induced by anticholinergic therapy.
Birket-Smith E
Acta Neurol Scand; 1974; 50(6):801-11. PubMed ID: 4155220
[No Abstract] [Full Text] [Related]
19. A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function.
McEvoy JP
J Clin Psychiatry; 1987 Sep; 48 Suppl():20-3. PubMed ID: 2887553
[TBL] [Abstract][Full Text] [Related]
20. Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from capsaicin-irritated skin in healthy volunteers.
Schaffler K; Reitmeir P
Arzneimittelforschung; 2004; 54(10):673-9. PubMed ID: 15553107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
